NTLA Intellia Therapeutics, Inc.

Nasdaq intelliatx.com


$ 12.77 $ 0.00 (0 %)    

Friday, 31-Oct-2025 05:21:16 EDT
QQQ $ 634.08 $ 0.00 (0 %)
DIA $ 475.71 $ 0.00 (0 %)
SPY $ 685.08 $ 0.00 (0 %)
TLT $ 90.26 $ 0.00 (0 %)
GLD $ 368.07 $ 0.00 (0 %)
$ 12.265
$ 11.78
$ 12.78 x 21
$ 12.87 x 2
-- - --
$ 5.90 - $ 28.25
12,677,079
na
1.32B
$ 2.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 10-31-2018 09-30-2018 10-Q
29 08-01-2018 06-30-2018 10-Q
30 05-01-2018 03-31-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 10-31-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-02-2017 03-31-2017 10-Q
35 03-14-2017 12-31-2016 10-K
36 11-01-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 06-03-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-18

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the p...

Core News & Articles

GPRK: 28% | Geopark shares are trading higher after Parex Resources submitted a proposal to acquire all outstanding shares of t...

 intellia-therapeutics-stock-is-diving-again-heres-why

Intellia Therapeutics shares are tumbling in after-hours trading on Wednesday. Here's what you need to know.

 intellia-therapeutics-announces-that-fda-has-placed-a-clinical-hold-on-the-investigational-new-drug-applications-for-the-magnitude-and-magnitude-2-phase-3-clinical-trials-for-nexiguran-ziclumeran

-SEC Filing

 wells-fargo-downgrades-intellia-therapeutics-to-equal-weight-lowers-price-target-to-17

Wells Fargo analyst Yanan Zhu downgrades Intellia Therapeutics (NASDAQ:NTLA) from Overweight to Equal-Weight and lowers the ...

 jmp-securities-maintains-market-outperform-on-intellia-therapeutics-lowers-price-target-to-29

JMP Securities analyst Silvan Tuerkcan maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and lowers the...

 barclays-maintains-overweight-on-intellia-therapeutics-lowers-price-target-to-24

Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target from ...

 rbc-capital-downgrades-intellia-therapeutics-to-sector-perform-lowers-price-target-to-14

RBC Capital analyst Luca Issi downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to Sector Perform and lowers th...

 bernstein-downgrades-intellia-therapeutics-to-market-perform-raises-price-target-to-145

Bernstein analyst William Pickering downgrades Intellia Therapeutics (NASDAQ:NTLA) from Outperform to Market Perform and rai...

 b-of-a-securities-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-30

B of A Securities analyst Greg Harrison maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...

 hc-wainwright--co-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the p...

 chardan-capital-maintains-buy-on-intellia-therapeutics-lowers-price-target-to-48

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION